Charles River Laboratories (CRL) Tops Q1 EPS by 37c, Updates Guidance
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $1.84, $0.37 better than the analyst estimate of $1.47. Revenue for the quarter came in at $707.1 million versus the consensus estimate of $691.09 million.
GUIDANCE:
Charles River Laboratories sees FY2020 EPS of $6.75-$7.10, versus the consensus of $6.44.
The Company’s revised guidance for revenue growth, earnings per share, and free cash flow is as follows:
2020 GUIDANCE | CURRENT |
| PRIOR | |
Revenue growth, reported | 4.5% – 8.0% |
| 13.0% – 14.5% | |
Less: Contribution from acquisitions (1) | ~(4.0%) |
| (4.0%) – (4.5%) | |
Unfavorable/(favorable) impact of foreign exchange | 0.5% – 1.0% |
| (1.0%) – (1.5%) | |
Revenue growth, organic (2) | 1.5% – 4.5% |
| 7.75% – 8.75% | |
GAAP EPS estimate | $4.25 – $4.60 |
| $5.20 – $5.35 | |
Acquisition-related amortization (3) | $1.75 – $1.80 |
| $1.65 – $1.70 | |
Charges related to global efficiency initiatives (4) | ~$0.05 |
| <$0.05 | |
Acquisition-related adjustments (5) | ~$0.20 |
| ~$0.25 | |
Other items (6) | $0.25 – $0.32 |
| $0.25 – $0.32 | |
Venture capital investment losses/(gains) (7) | $0.18 |
| -- | |
Non-GAAP EPS estimate | $6.75 – $7.10 |
| $7.45 – $7.60 | |
Free cash flow (8) | $325 – $350 million |
| $350 – $360 million | |
Footnotes to Guidance Table:
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.